各类子宫腺肌病与子宫内膜异位症:寻求最佳管理
本文为综述,讨论子宫腺肌病与子宫内膜异位症的激素治疗现状及非激素药物研发失败原因,强调需理解异位子宫内膜自然史以设计更好治疗方案。
要点
- 激素药物是目前治疗子宫内膜异位症或子宫腺肌病的主要手段。
- 非激素药物研发失败主因包括对异位子宫内膜自然史理解不足及副作用问题。
核心结论
- 除非对异位子宫内膜自然史有清晰的全局认识,否则药物研发中的「坑洞」和「死胡同」难以避免。
研究设计与样本
- 综述,检索范围涉及PubMed收录的超过34,000篇关于子宫内膜异位症或子宫腺肌病的文献。
主要发现
- 许多非激素药物研发项目失败的原因包括未能理解异位子宫内膜的自然史,以及候选药物出现的副作用数量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Currently, hormonal drugs are the mainstay for treating endometriosis or adenomyosis. Aside from staying within the "therapeutic window" and cutting off the hormonal support to the ectopic endometrium, none of these treatments were developed with a previously identified target. The current lack of innovation is humbling, especially considering that among >34,000 PubMed-indexed publications on endometriosis or adenomyosis, approximately 65% of them were published in the last 2 decades, many of them presumably with all the benefits of omics and molecular biology. One major reason for so many doomed research and development (R&D) projects on nonhormonal drugs is the failure to understand the natural history of the ectopic endometrium. Other reasons include, but are not limited to, the number of side effects that these nonhormonal drug candidates presented, which the developers were either unaware of or simply had ignored when pursuing a too narrowly minded development-a common cognitive trap known as invisible gorillas. Unless we have a clear global picture with a good grasp of the natural history of ectopic endometrium, "potholes" and "blind alleys" in drug R&D are difficult to avoid. This review shall explore some new concepts in the progression of ectopic endometrium and explain how these new perspectives offer insights for devising better therapeutic options, explain why some drug R&D projects for endometriosis or adenomyosis have failed, provide a critical analysis of some issues encountered in everyday practice, expose knowledge gaps in need of further research, and, finally, offer possible ways to circumvent hurdles and potholes and avoid cul-de-sacs in nonhormonal drug R&D.
引用
- Guo SW. Various types of adenomyosis and endometriosis: in search of optimal management. Fertil Steril. 2023. PMID: 36963717. doi:10.1016/j.fertnstert.2023.03.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。